UNION therapeutics receives FDA Fast Track designation for oral orismilast for the treatment of moderate to severe hidradenitis suppurativa

FDA's Fast Track designation for oral orismilast underscores the urgent need for new treatment options to fulfil the unmet medical need for people affected by...

Related Keywords

Taiwan ,Denmark ,Hong Kong ,Saunte ,Hovedstaden ,China ,Roskilde ,Sjæand ,Macau ,Hellerup ,Danish ,Innovent Biologics ,Kim Kj ,Sarah Toft ,Morten Boesen ,Gregorb Jemec ,Hidradenitis Suppurativa ,Zealand University Hospital Roskilde ,Conference Of The European Hidradenitis Suppurativa Foundation ,Ethics Committee ,Danish Medicines Agency ,Drug Administration ,Department Of Dermatology ,Fast Track ,Treatment Extension ,Founding Chairman ,Chief Executive Officer ,New Drug ,Mainland China ,Severe Hidradenitis Suppurativa ,European Hidradenitis Suppurativa ,Chief Financial Officer ,Union Therapeutics ,